A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Clinical trial NCT07636811 · RECRUITING

Trial details

NCT number: NCT07636811
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Start date: 2026-08-31
Primary completion: 2030-05-18
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.